• LAST PRICE
    8.0099
  • TODAY'S CHANGE (%)
    Trending Down-0.7751 (-8.8230%)
  • Bid / Lots
    7.6000/ 3
  • Ask / Lots
    8.7700/ 1
  • Open / Previous Close
    8.7700 / 8.7850
  • Day Range
    Low 8.0000
    High 8.7700
  • 52 Week Range
    Low 5.0000
    High 27.9000
  • Volume
    2,498
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 8.785
TimeVolumeADXN
11:47 ET1008.77
03:18 ET2918.325
03:41 ET2598.07
03:45 ET10008.0099
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADXN
Addex Therapeutics Ltd
14.0M
0.0x
---
United StatesAVTX
Avalo Therapeutics Inc
13.5M
0.0x
---
United StatesTLIS
Talis Biomedical Corp
16.4M
-0.3x
---
United StatesDOMH
Dominari Holdings Inc
12.9M
-0.5x
---
United StatesSNTI
Senti Biosciences Inc
15.6M
-0.2x
---
United StatesELAB
ELEVAI Labs Inc
12.6M
-2.5x
---
As of 2024-05-27

Company Information

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Contact Information

Headquarters
Chemin des Mines, 9PLAN-LES-OUATES, Switzerland 1202
Phone
---
Fax
---

Executives

Independent Non-Executive Chairman of the Board of Directors
Vincent Lawton
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Tim Dyer
Member of the Executive Management, Head of Translational Science
Mikhail Kalinichev
Member of the Executive Management, Head of Discovery - Biology
Robert Luetjens
Member of the Executive Management, Head of Finance
Lenaic Teyssedou

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.0M
Revenue (TTM)
$1.8M
Shares Outstanding
1.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.77
EPS
$-209.11
Book Value
$1.20
P/E Ratio
0.0x
Price/Sales (TTM)
7.7
Price/Cash Flow (TTM)
---
Operating Margin
-624.21%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.